Welcome
A centralised hub of content to support healthcare professionals using our medicines and services. Register now to unlock more content.
Register Now
Therapeutic Areas
Prostate Cancer
Access a range of therapy area resources to support the treatment of your prostate cancer patients.
Read More
AutoImmune
Discover the therapy area resources available to support your patients with autoimmune diseases.
Read More
Small Cell Lung Cancer
Access a range of therapy area resources to support the treatment of your small cell lung cancer patients.
Read More
Neutropenia
Access a range of resources to support the treatment of your neutropenia patients.
Read MoreProduct Portfolio
Link to Orgovyx® prescribing information is available at the bottom of the page.
Read More
Link to HETRONIFLY® prescribing information is available at the bottom of the page.
Read More
Link to Sondelbay® prescribing information is available at the bottom of the page.
Read More
Link to Camcevi® prescribing information is available at the bottom of the page.
Read More
Link to Osvyrti® prescribing information is available at the bottom of the page.
Read More
Link to Methofill prescribing information is available at the bottom of the page.
Read MoreEvents
ELCC 2025 Satellite Symposium: Professor Francesco Grossi
Watch Video
PROSCA 2024 Satellite Symposium: Professor Athanasios Papatsoris
At PROSCA 2024, Prof Athanasios Papatsoris shares insights on the role and impact of oral ADT in clinical practice, drawing from his first-hand experience and clinical expertise.
Watch Video
PROSCA 2024 Satellite Symposium: Professor Cosimo De Nunzio
At PROSCA 2024, Prof Cosimo De Nunzio outlines the opportunities that oral ADT provide for prostate cancer patients, particularly patients with cardiovascular risks and lower urinary tract symptoms (LUTS).
Watch Video
PROSCA 2024 Satellite Symposium: Professor Thomas Zilli
At PROSCA 2024, Prof Thomas Zilli shares insights on the role and impact of oral ADT in clinical practice, alongside his experiences using oral ADT for patients with lower urinary tract symptoms (LUTS) and those with existing cardiovascular comorbidities.
Watch Video
PROSCA 2024 Satellite Symposium: Professor Amit Bahl
At PROSCA 2024, Prof Amit Bahl discusses the role and impact of oral ADT in the treatment of prostate cancer, including the broader effects on cardiovascular health, bone health and patient lifestyle
Watch Video
EAU 2024 Satellite Symposium: Doctor Eva Hellmis, Professor Amit Bahl, Professor Romain Mathieu & Andrew Gabriel
During this meeting, Dr Eva Hellmis, Prof Amit Bahl, Prof Romain Mathieu and Andrew Gabriel talk through patient perspectives of ADT
Watch Video
EAU 2025 Satellite Symposium: Doctor Vérane Achard
At EAU 2025, Dr Vérane Achard shares insights on the impact of ADT for prostate cancer patients with lower urinary tract symptoms (LUTS), drawing from her first-hand experience and clinical expertise.
Watch Video
PROSCA 2023 Satellite Symposium: Professor Matthias Saar
At PROSCA 2023, Prof Matthias Saar presents the Intermittent ADT in the new era of hormonal therapy and highlights the alternative treatment options.
Watch Video
EAU 2025 Satellite Symposium: Doctor Teresa López Fernández
At EAU 2025, Dr Teresa López Fernández shares insights on the importance of assessing cardiovascular risk in prostate cancer patients and highlight the role of ADT in CV risk management.
Watch Video